They conducted an observational longitudinal study and analyzed the body composition of 27 outpatients with T2DM during the first week and up to 6 months after the initiation of treatment with SGLT-2 inhibitors using a BIA device (Body Composition Monitor (BCM), Fresenius). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.